Solid Biosciences Inc (OQ:SLDB)

Apr 03, 2024 04:05 pm ET
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to two newly hired employees. These grants were made...
Apr 01, 2024 07:45 am ET
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease...
Mar 27, 2024 07:00 am ET
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, and Gabriel Brooks, M.D., Chief...
Mar 13, 2024 07:44 am ET
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and...
Mar 07, 2024 07:00 am ET
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non-exclusive worldwide license and collaboration agreement with Armatus Bio for the use...
Mar 06, 2024 08:00 am ET
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Leerink Partners Global Biopharma...
Jan 16, 2024 08:00 am ET
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has been granted orphan drug designation (ODD) from the U.S. Food and Drug...
Jan 08, 2024 07:09 am ET
Solid Biosciences Announces $109 Million Private Placement
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of...
Jan 04, 2024 08:00 am ET
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the J.P Morgan...
Dec 07, 2023 08:00 am ET
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration...
Nov 22, 2023 08:00 am ET
Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Piper Sandler...
Nov 15, 2023 08:31 am ET
Thinking about buying stock in BioCardia, Microsoft, Beauty Health Co, Tivic Health Systems, or Solid Biosciences?
NEW YORK, Nov. 15, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BCDA, MSFT, SKIN, TIVC, and SLDB.
Nov 14, 2023 04:05 pm ET
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has received U.S. Food and Drug Administration (FDA) clearance of an...
Nov 09, 2023 08:00 am ET
Solid Biosciences to Participate at Jefferies London Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Jefferies London...
Nov 08, 2023 04:17 pm ET
Solid Biosciences Provides Third Quarter Business Update and Financial Results
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business...
Oct 02, 2023 08:00 am ET
Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for both neuromuscular and cardiac diseases, today announced the appointment of Gabriel Brooks, M.D., as Chief Medical Officer. “We are excited...
Sep 20, 2023 08:00 am ET
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the following three...
Sep 05, 2023 08:56 am ET
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the following two upcoming...
Aug 31, 2023 08:00 am ET
Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Citi 18th Annual BioPharma...
Aug 14, 2023 04:17 pm ET
Solid Biosciences Provides Second Quarter Business Update and Financial Results
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a business update. “We...
Jun 01, 2023 08:00 am ET
Solid Biosciences to Participate at the Jefferies Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in a fireside chat at the...
May 22, 2023 08:00 am ET
Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in a fireside chat at the...
May 16, 2023 08:00 am ET
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, will present positive preclinical data from studies of AVB-202, the company’s gene therapy candidate for the...
May 11, 2023 07:30 am ET
Solid Biosciences Provides First Quarter Business Update and Financial Results
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the first quarter ended March 31, 2023, and provided a business update. “In...
May 08, 2023 04:05 pm ET
Solid Biosciences to Present at JMP Securities Life Sciences Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the JMP Securities Life...
Apr 21, 2023 08:00 am ET
Solid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Solid management will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines...
Apr 13, 2023 08:00 am ET
Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 22nd Annual Needham...
Mar 23, 2023 08:00 am ET
Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a...
Mar 21, 2023 08:00 am ET
Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the BMO Biopharma...
Mar 07, 2023 08:00 am ET
Solid Biosciences to Present at Barclays Global Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Barclays Global Healthcare...
Feb 08, 2023 08:00 am ET
Solid Biosciences to Present at SVB Securities Global Biopharma Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the SVB Securities Global...
Jan 26, 2023 08:00 am ET
Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy
The Pathway Development Consortium (PDC), a public-private collaboration founded by REGENXBIO Inc. (Nasdaq: RGNX) and Solid Biosciences Inc. (Nasdaq: SLDB), today announced the publication of a peer-reviewed manuscript, Micro-dystrophin expression...
Jan 11, 2023 08:00 am ET
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, and Phlox Therapeutics, a biotech company pioneering a novel approach to gene therapies to alleviate and cure...
Jan 10, 2023 08:00 am ET
Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today outlined its strategic priorities for 2023. These announcements are being made in advance of Solid’s...
Jan 09, 2023 04:26 pm ET
Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed Chief Financial Officer and Treasurer, Kevin...
Jan 09, 2023 08:01 am ET
Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the appointment of Kevin Tan, CFA, a seasoned industry professional, as Chief Financial Officer....
Jan 09, 2023 08:00 am ET
Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan...
Dec 05, 2022 04:35 pm ET
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for patients with neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed President and Chief...
Dec 05, 2022 07:30 am ET
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the closing of its acquisition of AavantiBio, a privately held gene therapy company...
Dec 01, 2022 04:15 pm ET
Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the results of the special meeting of the stockholders held on December 1, 2022. At...
Nov 22, 2022 08:00 am ET
Solid Biosciences to Participate at the Piper Sandler 34th Annual Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder of Solid, Bo...
Nov 18, 2022 07:50 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBCF, RCKT, RCOR, SLDB
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seacoast Banking Corporation of...
Nov 17, 2022 04:53 pm ET
EQUITY ALERT: The M&A Class Action Firm Continues Investigating the Merger - HVBC, IMRA, SLDB, SMBC
NEW YORK, Nov. 17, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Nov 15, 2022 04:17 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SLDB, LFG, BNFT, ABMD
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Nov 15, 2022 10:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JVA, SLDB, FCRD, SPNE
NEW YORK, Nov. 15, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 13, 2022 02:02 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISR, SLDB, POSH, OFIX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Isoray, Inc. (NYSE: ISR)’s merger with...
Nov 12, 2022 10:30 am ET
SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Solid Biosciences Inc. (“the Company”) (NasdaqGS: SLDB) with AavantiBio, Inc. pursuant to which shareholders of AavantiBio are expected to own approximately 15% of the combined company, subject to certain adjustments. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.
Nov 10, 2022 09:40 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JVA, SLDB, FCRD, SPNE
NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 10, 2022 07:34 am ET
Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today reported financial results for the third quarter ended September 30, 2022 and provided a...
Nov 06, 2022 01:07 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MVBF, SMBC, SPNE, SLDB
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: MVB Financial Corp. (NASDAQ: MVBF)’s...
Nov 04, 2022 05:27 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – LFG, AAWW, BNFT, SLDB
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Oct 27, 2022 08:00 am ET
Solid Biosciences Announces a 1-for-15 Reverse Stock Split
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will implement a 1-for-15 reverse split of its common stock (Reverse Stock...
Oct 17, 2022 08:00 am ET
Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle
Solid Biosciences, a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), presented additional data characterizing AAV-SLB101, a novel adeno-associated virus (AAV) vector designed for improved...
Oct 16, 2022 10:06 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OIIM, SLDB, POSH, SPNE
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: O2Micro International Limited (NASDAQ:...
Oct 13, 2022 08:00 am ET
Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function
Solid Biosciences, a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today reported additional positive one-year data from the IGNITE DMD Phase I/II clinical trial of its microdystrophin...
Oct 03, 2022 10:55 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SLDB, RFP, SBTX, SGFY, COWN
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sep 30, 2022 05:34 pm ET
SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Solid Biosciences Inc. (“the Company”) (NasdaqGS: SLDB) with AavantiBio, Inc. pursuant to which shareholders of AavantiBio are expected to own approximately 15% of the combined company, subject to certain adjustments. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.
Sep 30, 2022 10:02 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSNT, SLDB, JVA
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SilverSun Technologies, Inc. (NASDAQ:...
Sep 30, 2022 09:39 am ET
SLDB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Solid Biosciences Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Solid Biosciences Inc. (NASDAQ: SLDB) and AavantiBio, Inc. is fair to Solid shareholders.
Sep 30, 2022 07:00 am ET
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), and AavantiBio, Inc., a privately-held gene therapy company focused on transforming the lives of...
Sep 29, 2022 08:00 am ET
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Co-Founder, President and CEO, and Carl Morris, Ph.D., Chief...
Aug 11, 2022 07:53 am ET
Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today reported financial results for the second quarter ended June 30, 2022 and provided a business...
Jun 23, 2022 08:00 am ET
Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming scientific and patient...
Jun 02, 2022 08:30 am ET
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President,...
Jun 02, 2022 08:00 am ET
Solid Biosciences to Participate at the Jefferies Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, Co-Founder and President, and Carl...
May 17, 2022 08:00 am ET
Solid Biosciences to Present at ASGCT 25th Annual Meeting and CureDuchenne 2022 FUTURES National Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming scientific and patient...
Apr 27, 2022 07:30 am ET
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced an update to its strategic priorities to focus on developing SGT-001 and SGT-003....
Apr 25, 2022 08:00 am ET
Solid Biosciences Management to Host Call on April 27, 2022 to Discuss Updated Corporate Strategy and First Quarter 2022 Financial Results
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2022 financial results before the market opens...
Mar 14, 2022 08:09 am ET
Solid Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and 2-Year Efficacy and Safety Data from the Ongoing Phase I/II IGNITE DMD Clinical Trial of SGT-001
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today provided an update from the ongoing IGNITE DMD Phase I/II clinical trial, as well as a...
Feb 10, 2022 08:00 am ET
Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, and Carl Morris, PhD, Chief...
Jan 10, 2022 08:00 am ET
Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today provided an update on its 2022 strategic priorities and other business initiatives in advance...
Jan 06, 2022 08:00 am ET
Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at...
Jan 04, 2022 08:00 am ET
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Human Resources
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President, Human...
Dec 10, 2021 09:40 am ET
Thinking about buying stock in Insignia Systems, RLX Technology, Solid Biosciences, Southwest Airlines, or Infinity Pharmaceuticals?
NEW YORK, Dec. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISIG, RLX, SLDB, LUV, and INFI.
Dec 07, 2021 09:31 am ET
Thinking about buying stock in Gevo, Carnival Corp, Ardelyx, Spirit Realty Capital, or Solid Biosciences?
NEW YORK, Dec. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEVO, CCL, ARDX, SRC, and SLDB.
Nov 03, 2021 07:05 am ET
Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today provided a business update as well as financial results for the third quarter ended September...
Nov 02, 2021 07:30 am ET
Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development
The Pathway Development Consortium (PDC), a new public-private collaboration founded by REGENXBIO Inc. (Nasdaq: RGNX) and Solid Biosciences Inc. (Nasdaq: SLDB), today announced the publication of a draft white paper, Draft Framework for AAV Gene...
Oct 21, 2021 08:00 am ET
Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Co-Founder, President and Chief Executive Officer, and Carl...
Oct 04, 2021 08:00 am ET
Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
Solid Biosciences Inc. (Solid, Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), and Forge Biologics, a cell and gene therapy-focused contract development and manufacturing organization (CDMO), announced a partnership to advance the development and manufacturing of SGT-003, Solid’s next generation gene therapy program for Duchenne. SGT-003 is a preclinical candidate that combines a next-generation and rationally designed capsid with Solid’s proprietary nNOS-containing microdystrophin and has demonstrated enhanced
Sep 29, 2021 07:00 am ET
Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today reported additional positive pulmonary function data from the first six patients in the...
Sep 23, 2021 09:31 am ET
Thinking about buying stock in Northern Dynasty Minerals, FuelCell Energy, Cardiff Oncology, SoFi Technologies, or Solid Biosciences?
NEW YORK, Sept. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAK, FCEL, CRDF, SOFI, and SLDB.
Sep 23, 2021 06:00 am ET
Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
Patient reported outcomes showed sustained improvements at 1.5 years compared to patient baseline and natural history data - - No new drug-related safety findings for a period of up to 3.5 years - CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE...
Sep 20, 2021 04:05 pm ET
Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the presentation of long-term data from Patients 4-6 in the ongoing IGNITE DMD...
Sep 20, 2021 04:01 pm ET
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Carl Morris, Ph.D., Chief...
Aug 24, 2021 08:00 am ET
Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, will discuss Solid’s robust,...
Aug 19, 2021 08:05 am ET
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President,...
Aug 19, 2021 08:00 am ET
Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Michael Inbar, CPA, MBA, has joined the Company as Senior Vice President,...
Aug 16, 2021 04:11 pm ET
Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today provided a second quarter 2021 business update as well as financial results for the quarter...
Jul 02, 2021 08:00 am ET
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Senior Vice President,...
Jul 01, 2021 08:00 am ET
Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the hiring of Roxana Donisa Dreghici, M.D. as Senior Vice President, Clinical...
Jun 09, 2021 08:30 am ET
Thinking about buying stock in Aethlon Medical, Checkpoint Therapeutics, ContextLogic, Clean Energy Fuels, or Solid Biosciences?
NEW YORK, June 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AEMD, CKPT, WISH, CLNE, and SLDB.
Jun 07, 2021 07:35 am ET
Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Regulatory Officer,...
Jun 07, 2021 07:30 am ET
Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulatory Officer,...
May 26, 2021 07:30 am ET
Solid Biosciences to Present at the Jefferies Virtual Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, will present at the Jefferies...
May 25, 2021 04:03 pm ET
Solid Biosciences to Present at Upcoming Scientific Conferences
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate at the following upcoming scientific conferences:...
May 14, 2021 07:30 am ET
Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today provided a first quarter 2021 business update, which includes updates on two additional...
May 11, 2021 08:00 am ET
Solid Biosciences to Host First Quarter 2021 Financial Results and Business Update Call on May 14, 2021
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2021 financial results before the market opens...
May 04, 2021 08:00 am ET
Solid Biosciences Highlights Expertise in AAV Gene Therapy with Multiple Abstracts to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the presentation of three abstracts at the upcoming American Society of Gene & Cell...
Apr 20, 2021 07:30 am ET
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Louise Perry, Head of...
Apr 12, 2021 07:30 am ET
Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Georgia Keresty, Ph.D., M.P.H., to the...
Mar 25, 2021 07:30 am ET
Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will participate in a panel...
Mar 23, 2021 04:22 pm ET
Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the closing of its previously announced underwritten public offering of 25,000,000...
Mar 18, 2021 09:14 pm ET
Solid Biosciences Announces Pricing of Public Offering of Common Stock
Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has priced an underwritten public offering of 21,739,131 shares of its...
Mar 17, 2021 04:20 pm ET
Solid Biosciences Announces Proposed Public Offering of Common Stock
Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has commenced an underwritten public offering of $85 million of shares of...
Mar 15, 2021 04:15 pm ET
Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort
Patient 7, safely dosed with SGT-001, experienced transient and manageable adverse events, none of which were serious; six patients previously dosed showed no new drug-related safety findings 17-37 months post dosing; screening and enrollment of...
Mar 04, 2021 07:35 am ET
Solid Biosciences Reports Inducement Grant to New Chief Legal Officer
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Legal Officer, Erin...
Mar 04, 2021 07:30 am ET
Solid Biosciences Announces Appointments to Management Team and Board of Directors
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), announced today that Erin Powers Brennan has joined the company as Chief Legal Officer and Joel...
Feb 24, 2021 04:24 pm ET
Efficacy and Safety Data from Solid Biosciences’ Ongoing IGNITE DMD Phase I/II Clinical Trial to be Presented at the 2021 MDA Clinical & Scientific Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), announced that one-year efficacy and safety data from the ongoing IGNITE-DMD Phase I/II study of...
Feb 17, 2021 07:30 am ET
Solid Biosciences to Present at Upcoming Investor Conferences
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Technology Officer, and Cathryn Clary, MD, MBA,...
Jan 06, 2021 07:30 am ET
Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at...
Dec 11, 2020 07:30 am ET
Solid Biosciences Announces $90 Million Private Placement
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has entered into a securities purchase agreement with a select group of...
Nov 05, 2020 07:00 am ET
Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today reported financial results for the third quarter ended September 30, 2020 and provided a...
Nov 03, 2020 07:30 am ET
Solid Biosciences to Host Third Quarter 2020 Financial Results and Business Update Call on November 5, 2020
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release third quarter 2020 financial results before the market opens...
Oct 23, 2020 08:00 am ET
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy
Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences...
Oct 02, 2020 07:30 am ET
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Jennifer Ziolkowski, Chief Financial Officer, Joel Schneider, Chief Technology...
Oct 01, 2020 07:30 am ET
Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold...
Jul 29, 2020 09:12 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Solid Biosciences Inc. - SLDB
NEW YORK, July 29, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 24, 2020 05:51 pm ET
Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical Hold
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, today announced that it received written communication from the U.S. Food and Drug Administration (FDA) that...
Jun 18, 2020 07:00 am ET
Solid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced today the appointment of board member Ian F. Smith as Chairman of the Board. Mr. Smith succeeds...
May 22, 2020 07:00 am ET
Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020
Solid Biosciences Inc. (Nasdaq: SLDB) today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, its 2020 Annual Meeting of...
May 14, 2020 07:00 am ET
Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual Meeting
Solid Biosciences Inc. (Nasdaq: SLDB) today announced the presentation of clinical biomarker data from its SGT-001 microdystrophin gene therapy clinical trial for the treatment of Duchenne muscular dystrophy (Duchenne) on May 13 at the American...
May 07, 2020 07:22 am ET
Solid Biosciences Provides Update regarding SGT-001 Phase I/II Clinical Hold on IGNITE DMD
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that it received written communication from the U.S. Food and Drug Administration (FDA) regarding...
Apr 16, 2020 07:00 am ET
Solid Biosciences Announces Appointment of Ian F. Smith to its Board of Directors
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced today the appointment of Ian F. Smith to its board of directors effective April 15, 2020. Mr. Smith...
Mar 12, 2020 07:00 am ET
Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the fourth quarter and full year ending December 31, 2019 and provided a business update. “We are working to advance our lead program, SGT-001, a gene therapy candidate for...
Jan 09, 2020 08:00 am ET
Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001
Solid Biosciences Inc. (Nasdaq: SLDB) today announced changes to its organizational structure to create a leaner company focused on advancing SGT-001, a gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne). In...
Dec 18, 2019 06:30 am ET
Solid Biosciences Provides Data Update from SGT-001 Development Program
Solid Biosciences Inc. (Nasdaq: SLDB) today announced biomarker data from two patients dosed in the second cohort of IGNITE DMD, its Phase I/II study of SGT-001. SGT-001 is the company’s gene transfer candidate under investigation for Duchenne...
Nov 12, 2019 05:51 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Solid Biosciences Inc. - SLDB
Pomerantz LLP is investigating claims on behalf of investors of  Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ:  SLDB).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Nov 12, 2019 06:45 am ET
Solid Biosciences Provides SGT-001 Program Update
Solid Biosciences Inc. (Nasdaq: SLDB) today provided a clinical update on SGT-001 and reported that the U.S. Food and Drug Administration (FDA) has notified the company that IGNITE DMD, its Phase I/II study of SGT-001, has been placed on clinical...
Oct 16, 2019 08:42 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Solid Biosciences Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, Oct. 16, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Solid Biosciences Inc. (NASDAQ: SLDB).
Oct 02, 2019 07:30 am ET
Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference
Solid Biosciences Inc. (Nasdaq: SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at the upcoming Chardan Annual Genetic Medicines Conference at 8:30 a.m. ET on...
Sep 05, 2019 07:30 am ET
Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disord
Solid Biosciences Inc. (Nasdaq: SLDB) today announced the publication of a review article in the journal Neuromuscular Disorders¹ that summarizes the evidence supporting the function of microdystrophin-associated neuronal nitric oxide synthase...
Aug 14, 2019 07:25 am ET
Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update
Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the second quarter ended June 30, 2019 and provided a business update. “We continue to execute on our mission to bring transformative therapies to patients with...
Jul 26, 2019 07:25 am ET
Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors
Solid Biosciences Inc. (Nasdaq: SLDB) today announced that it has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $60 million private placement, which is expected to close...
May 16, 2019 03:00 pm ET
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ: SLDB). Such investors are encouraged to obtain additional...
May 13, 2019 04:10 pm ET
Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update
Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the first quarter ended March 31, 2019 and provided a business update. “We have continued to advance our programs for Duchenne muscular dystrophy over the last few months,...
Apr 18, 2019 08:50 am ET
Research Report Identifies Solid Biosciences, Zion Oil & Gas, Banner, Senestech, Kingsway Financial Services, and Marathon Patent Group with Renewed Outlook — Fundamental Analysis, Calculating Forward
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Solid Biosciences Inc. (NASDAQ:SLDB), Zion Oil & Gas Inc (NASDAQ:ZN), Banner...
Apr 15, 2019 04:01 pm ET
Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting
Solid Biosciences Inc. (NASDAQ:SLDB) today announced that preclinical data from its gene therapy program for Duchenne muscular dystrophy (DMD) will be presented at the 22nd Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)...
Mar 13, 2019 07:30 am ET
Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update
Solid Biosciences Inc. (NASDAQ: SLDB) today reported financial results for the fourth quarter and fiscal year ended December 31, 2018 and provided a business update. “In our first year as a public company, we have significantly advanced our...
Feb 07, 2019 11:22 am ET
SHAREHOLDER ALERT: Investigation of Solid Biosciences Inc. Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether certain statements made by Solid Biosciences, Inc. (“Solid Biosciences” or the “Company”) (NASDAQ: SLDB) complied with federal securities laws. On February 7, 2019, the price of Solid Biosciences shares fell significantly following the Company’s announcement of preliminary findings from IGNITE DMD, the Company’s Phase I/II dose-ascending clinical trial evaluating the safety and efficacy of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular dystrophy (DMD).
Feb 07, 2019 06:45 am ET
Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy
Solid Biosciences (Nasdaq: SLDB) announced today preliminary findings from IGNITE DMD, the Company’s Phase I/II dose-ascending clinical trial evaluating the safety and efficacy of SGT-001 microdystrophin gene transfer for the treatment of Duchenne...
Jan 02, 2019 08:00 am ET
Solid Biosciences to Present at the J.P. Morgan Healthcare Conference
Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot, Co-Founder, Chief Executive Officer and President of Solid Biosciences will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9th at 7:30 am PT....
Nov 21, 2018 07:45 am ET
Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook — Fundamental A
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE), Allied Motion...
Nov 13, 2018 07:00 am ET
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business Update
Solid Biosciences Inc. (NASDAQ: SLDB) today reported financial results for the third quarter ended September 30, 2018 and provided a business update. “We are pleased to have made significant progress toward our goal of bringing meaningful...
Nov 09, 2018 07:30 am ET
Solid Biosciences to Present at the Credit Suisse Healthcare Conference
Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 at 2:50 pm MT in Scottsdale, Arizona. The Credit Suisse Healthcare Conference...
Oct 05, 2018 04:05 pm ET
Solid Biosciences to Present at the Chardan Genetic Medicines Conference
Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will participate in a question and answer format presentation at the Chardan Capital Markets 2nd Annual Genetic Medicines Conference on Tuesday, October 9, 2018 at 7:30 am ET in...
Oct 01, 2018 08:00 am ET
Solid Biosciences to Present at the Cell & Gene Meeting on the Mesa
Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Cell Gene Meeting on the Mesa on Wednesday, October 3, 2018 at 3:30 pm PT in La Jolla, California. The Cell Gene Meeting on the Mesa is organized by the...
Sep 13, 2018 07:30 am ET
Solid Biosciences Welcomes Sukumar Nagendran, M.D., To Its Board Of Directors
Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Sukumar Nagendran, M.D., has been elected to its Board of Directors. Dr. Nagendran brings to Solid more than 30 years of experience in key functional areas, including gene therapy...
Aug 10, 2018 07:30 am ET
Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update
Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the second quarter ended June 30, 2018 and provided a business update. “It is an exciting time for Solid as we work to advance our innovative pipeline designed to address...
Jun 26, 2018 07:30 am ET
Solid Biosciences Welcomes Industry Expert Dr. Martin Freed To Its Board Of Directors
Solid Biosciences Inc. (NASDAQ:SLDB) today announced that Martin Freed, M.D., F.A.C.P., a biopharmaceutical expert with more than 25 years of industry experience, has joined its Board of Directors. Additionally, Gilad Hayeem, Solid’s Co-Founder,...
Jun 18, 2018 07:00 am ET
Solid Biosciences Announces FDA Removes Clinical Hold on SGT-001
Solid Biosciences Inc. (NASDAQ:SLDB) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on IGNITE DMD, the Company’s Phase I/II clinical trial for its investigational microdystrophin gene transfer,...
May 29, 2018 01:38 pm ET
Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the May 29th Deadline in the Class Action Lawsuit Against Solid Biosciences Inc. (SLDB)
Glancy Prongay Murray LLP (“GPM”) reminds investors of the May 29, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Solid Biosciences Inc. (“Solid Biosciences” or the “Company”)...
May 29, 2018 09:44 am ET
DEADLINE TODAY: Kaskela Law Alerts Solid Biosciences, Inc. Investors of Important Deadline
Kaskela Law LLC alerts Solid Biosciences, Inc. (NASDAQ: SLDB) (“Solid Biosciences” or the “Company”) investors that a class action lawsuit has been filed on behalf of investors who purchased or acquired Solid Biosciences common stock between January 25, 2018 and March 14, 2018, inclusive (the “Class Period”).
May 27, 2018 10:50 pm ET
SOLID BIOSCIENCES 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Solid Biosciences I
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (NasdaqGS: SLDB). Investor losses must relate to purchases of the Company’s shares between January 25, 2018, and March 14, 2018 or in its January 25, 2018 initial public offering. This action is pending in the United States District Court for the District of Massachusetts.
May 26, 2018 08:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Solid Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline – SLDB
Pomerantz LLP announces that a class action lawsuit has been filed against Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ: SLDB) and certain of its officers.   The class action, filed in United States District Court, District...
May 25, 2018 10:50 pm ET
SOLID BIOSCIENCES 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (NasdaqGS: SLDB). Investor losses must relate to purchases of the Company’s shares between January 25, 2018, and March 14, 2018 or in its January 25, 2018 initial public offering. This action is pending in the United States District Court fo
May 25, 2018 04:42 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Solid Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline – SLDB
Pomerantz LLP announces that a class action lawsuit has been filed against Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ:SLDB) and certain of its officers.   The class action, filed in United States District Court, District...
May 25, 2018 03:56 pm ET
SOLID BIOSCIENCES LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Solid Biosciences Inc. To Contact The Firm
NEW YORK, May 25, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB) of the May 29, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
May 25, 2018 10:45 am ET
FINAL DEADLINE NOTICE: Shareholder Class Action Lawsuit Against Solid Biosciences, Inc.
Kaskela Law LLC announces that a shareholder class action complaint has been filed against Solid Biosciences, Inc. (NASDAQ: SLDB) (“Solid Biosciences” or the “Company”) on behalf of purchasers of the Company’s securities between January 25, 2018 and March 14, 2018, inclusive (the “Class Period”).
May 24, 2018 07:35 pm ET
SLDB $100,000 Threshold: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Solid Biosciences Inc. Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired securities of Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ:SLDB) securities...
May 22, 2018 07:55 pm ET
The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Solid Biosciences Inc. (SLDB)
Law Offices of Howard G. Smith reminds investors of the May 29, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ: SLDB) securities between January 22, 2018, and March 14, 2018,
May 22, 2018 04:49 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Solid Biosciences Inc. To Contact The Firm
Faruqi Faruqi, LLP, a leading national securities law firm, reminds investors in Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ:SLDB) of the May 29, 2018 deadline to seek the role of lead plaintiff in a federal securities...
May 21, 2018 09:47 pm ET
Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Solid Biosciences Inc. (SLDB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the May 29, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ:
May 19, 2018 08:00 am ET
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Solid Biosciences
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of a class who purchased Solid Biosciences Inc. (Nasdaq: SLDB) (“Solid” or the “Company”) securities pursuant and/or traceable to Solid’s false and misleading Registration Statement and Prospectus issued in connection with the Company’s initial public offering on or about January 25, 2018 and/or on the open market between January 25
May 18, 2018 10:50 pm ET
SOLID BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (Nasdaq:SLDB), if they purchased the...
May 18, 2018 06:45 pm ET
Solid Biosciences Announces New Preclinical Data at the American Society of Gene and Cell Therapy Annual Meeting
Solid Biosciences Inc. (NASDAQ:SLDB) today announced the presentation of new preclinical data from its gene therapy development programs for Duchenne muscular dystrophy (DMD). New data for SGT-001, the Company’s lead microdystrophin gene transfer...
May 15, 2018 04:34 pm ET
Solid Biosciences Announces Upcoming Preclinical Data Presentations
Solid Biosciences Inc. (NASDAQ:SLDB) today announced that new preclinical data from its Duchenne muscular dystrophy (DMD) programs, including its lead gene transfer candidate, SGT-001, will be presented at the 21st Annual Meeting of The American...
May 14, 2018 02:41 pm ET
Bragar Eagel & Squire, P.C. Remind Investors That a Class Action Lawsuit Has Been Filed Against Solid Biosciences, Inc. (SLDB) and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Solid Biosciences, Inc. (NASDAQ: SLDB) securities issued in connection with the Company’s January 25, 2018 initial public offering (“IPO”), or on the open market between January 25, 2018 and March 14, 2018 (the “Class Period”). Investors have until May 29, 2018 to apply to the Court to be appointed as lead plaintiff in the law
May 12, 2018 08:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Solid Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline
Pomerantz LLP announces that a class action lawsuit has been filed against Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ: SLDB) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under index number 18-cv-10639, is on behalf of a class consisting of investors who purchased or otherwise acquired Solid’s securities: (1) pursuant and/or traceable to Solid’s false and misleading Registration Statement and Prospectus, issued in connection with the Compan
May 11, 2018 10:50 pm ET
SOLID BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit
Kahn Swick Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid...
May 10, 2018 07:30 am ET
Solid Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the first quarter ended March 31, 2018 and provided a business update. “The first quarter of 2018 marked Solid’s entry into public markets with the completion of our initial...
May 07, 2018 11:31 am ET
Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for Solid Biosciences, Inc. Investors – SLDB
Kessler Topaz Meltzer Check, LLP reminds Solid Biosciences, Inc. (Nasdaq:SLDB) (“Solid Biosciences” or the “Company”) investors that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on...
May 06, 2018 01:45 pm ET
Kaskela Law LLC: Shareholder Class Action Filed Against Solid Biosciences, Inc. - SLDB
Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Solid Biosciences, Inc. (NASDAQ:SLDB) (“Solid Biosciences” or the “Company”) on behalf of purchasers of the Company’s securities between January 25, 2018 and...
May 04, 2018 10:50 pm ET
SOLID BIOSCIENCES SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (NasdaqGS: SLDB), if they purchased the Company’s shares between January 25, 2018, and March 14, 2018 (the “Class Period”) or in its January 25, 2018 initial public offering (“IPO”). This action is pending in the United States District Court for the District of Massachusetts.
May 02, 2018 06:35 pm ET
WeissLaw LLP: Solid Biosciences Inc. is the Subject of a Legal Investigation
NEW YORK, May 2, 2018 /PRNewswire/ -- WeissLaw LLP announced that a class action was filed in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired shares of Solid Biosciences Inc. ("SLDB" or the "Company") (NASDAQ: SLDB) from January 25, 2018 through April 18, 2018.  The action seeks to pursue remedies and recover compensable damages caused by SLDB's Board of Directors under the Securities Act of 1933, and the Securities Exchange Act of 1934.
May 02, 2018 10:00 am ET
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Solid Biosciences Inc. (SLDB) and Lead Plaintiff Deadline - May 28, 2018
NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Solid Biosciences Inc. ("Solid" or the "Company") (NASADAQ:SLDB) and certain of...
May 01, 2018 05:33 pm ET
The Klein Law Firm Reminds Investors of a Class Action on Behalf of Solid Biosciences Inc. Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (SLDB)
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Solid Biosciences Inc. (NASDAQ: SLDB) who purchased shares pursuant to the January...
Apr 29, 2018 08:00 am ET
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Solid Biosciences Inc. (Nasdaq: SLDB) To Contact Brower Piven Before The Lead Plaintiff De
STEVENSON, Md., April 29, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of...
Apr 28, 2018 09:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Solid Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline - SLDB
NEW YORK, April 28, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB) and certain of its officers.  The class action, filed in United States District Court, District of Massachusetts, and docketed under index number 18-cv-10639, is on behalf of a class consisting of investors who purchased or otherwise acquired Solid's securities: (1) pursuant and/or traceable to Solid's false and misleading Registration Statement and Prospectus, issued in connection with the Company's i
Apr 27, 2018 10:50 pm ET
SOLID BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB
NEW ORLEANS, April 27, 2018 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (NasdaqGS: SLDB), if they purchased the Company's shares between January 25, 2018, and March 14, 2018 (the "Class Period") or in its January 25, 2018 initial public offering ("IPO").  This action is pending in the United States District Court for the District of Massachusetts.
Apr 27, 2018 04:55 pm ET
SLDB LOSS NOTICE: Rosen Law Firm Reminds Solid Biosciences Inc. Investors of Important Deadline in Class Action
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Solid Biosciences Inc. (NASDAQ: SLDB): (1) in Solid Biosciences’ initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive (the “Class Period”) of the important May 29, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Solid Biosciences investors under the federal securities laws.
Apr 27, 2018 03:01 pm ET
SLDB EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Solid Biosciences Inc. and a Lead Plaintiff Deadline of May 29, 2018
NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors...
Apr 26, 2018 03:49 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Solid Biosciences Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – SLDB
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
Apr 25, 2018 03:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Solid Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline – SLDB
NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ:SLDB) and certain of its officers.   The class action, filed...
Apr 24, 2018 02:00 pm ET
SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed Against Solid Biosciences, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Solid Biosciences, Inc. (Nasdaq: SLDB) (“Solid Biosciences” or the “Company”) shareholders that a class action lawsuit has been filed on behalf of purchasers of Solid Biosciences securities between January 25, 2018 and March 14, 2018, inclusive (the “Class Period”).
Apr 22, 2018 01:20 pm ET
Johnson Fistel, Announces Investigations of FAT Brands Inc., Solid Biosciences Inc., and Grupo Televisa S.A.B.; Investors with Losses Encouraged to Contact Firm
SAN DIEGO, April 22, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against FAT Brands Inc., Solid Biosciences Inc., and Grupo Televisa S.A.B., as detailed below:
Apr 20, 2018 10:50 pm ET
SOLID BIOSCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (NasdaqGS: SLDB), if they purchased the Company’s shares between January 25, 2018, and March 14, 2018 (the “Class Period”) or in its January 25, 2018 initial public offering (“IPO”). This action is pending in the United States District Court for the District of Massachusetts.
Apr 19, 2018 04:00 pm ET
The Klein Law Firm Reminds Investors of a Class Action on Behalf of Solid Biosciences Inc. Shareholders and a Lead Plaintiff Deadline of May 29, 2018
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Solid Biosciences Inc. (NASDAQ: SLDB) who purchased shares pursuant to the January 25, 2018 initial public offering and/or between January 25, 2018 and March 14, 2018. The action, which was filed in the United States District Court for the District of Massachusetts, alleges that the Company violated federal securities laws.
Apr 19, 2018 06:00 am ET
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Solid Biosciences Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of a class who purchased Solid Biosciences Inc. (Nasdaq: SLDB) (“Solid” or the “Company”) securities pursuant and/or traceable to Solid’s false and misleading Registration Statement and Prospectus issued in connection with the Company’s initial public offering on or about January 25, 2018 and/or on the open market between January 25
Apr 18, 2018 04:23 pm ET
SLDB EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Solid Biosciences Inc. and a Lead Plaintiff Deadline of May 29, 2018
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Solid Biosciences Inc. ("Solid Biosciences ") (NASDAQ: SLDB) securities pursuant to the January 25, 2018 initial public offering and/or between January 25, 2018 and March 14, 2018.
Apr 18, 2018 07:30 am ET
Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy
- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -
Apr 16, 2018 06:00 pm ET
Safirstein Metcalf LLP Announces That A Class Action Has Been Filed Against Solid Biosciences Inc. –  SLDB
NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- Safirstein Metcalf LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities...
Apr 16, 2018 04:00 pm ET
The Klein Law Firm Announces a Class Action on Behalf of Solid Biosciences Inc. Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (SLDB)
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Solid Biosciences Inc. (NASDAQ: SLDB) who purchased shares pursuant to the January 25, 2018 initial public offering and/or between January 25, 2018 and March 14, 2018. The action, which was filed in the United States District Court for the District of Massachusetts, alleges that the Company violated federal securities laws.
Apr 13, 2018 10:50 pm ET
SOLID BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB
NEW ORLEANS, April 13, 2018 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc....
Apr 13, 2018 04:00 pm ET
The Klein Law Firm Announces a Class Action Commenced on Behalf of Solid Biosciences Inc. Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (SLDB)
NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Solid Biosciences Inc. (NASDAQ:SLDB) who purchased shares pursuant to the January 25,...
Apr 12, 2018 05:00 pm ET
SLDB INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Solid Biosciences Inc. and a Lead Plaintiff Deadline of May 29, 2018
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Solid Biosciences Inc. ("Solid Biosciences ") (NASDAQ: SLDB) securities pursuant to the January 25, 2018 initial public offering and/or between January 25, 2018 and March 14, 2018.
Apr 10, 2018 06:03 pm ET
SLDB SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Solid Biosciences Inc. and a Lead Plaintiff Deadline of May 29, 2018
NEW YORK, April 10, 2018 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.